Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

0REU

Pharma Equity Group A/s (0REU)

Pharma Equity Group A/s
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:LSE:0REU
FechaHoraFuenteTítuloSímboloCompañía
23/04/202404:45UK RegulatoryMajor shareholder announcement - Pharma Equity Group A/SLSE:0REUPharma Equity Group A/s
16/04/202410:29UK RegulatoryPassing of the General Meeting of Pharma Equity Group A/SLSE:0REUPharma Equity Group A/s
10/04/202407:21UK RegulatoryThe Board of Director's decision to issue convertible loansLSE:0REUPharma Equity Group A/s
05/04/202404:22UK RegulatoryPharma Equity Group’s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company’s patented drug candidate RNX-051.LSE:0REUPharma Equity Group A/s
25/03/202407:06UK RegulatoryNotice convening the annual general meeting in Pharma Equity Group A/SLSE:0REUPharma Equity Group A/s
22/03/202403:00UK RegulatoryPharma Equity Group A/S (PEG) enters into an agreement with Danske Bank on the exercise of market maker in the PEG share, fund code: DK0061155009LSE:0REUPharma Equity Group A/s
21/03/202410:32UK RegulatoryCompletion of subscription of convertible loansLSE:0REUPharma Equity Group A/s
20/03/202402:58UK RegulatoryPharma Equity Group A/S - Annual Report 2023LSE:0REUPharma Equity Group A/s
05/03/202403:11UK RegulatoryPharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has received notification from the European Patent Office (EPO) regarding the decision to grant their patent for drug compositions for promoting the healing of wounds (RNX-022).LSE:0REUPharma Equity Group A/s
 Showing the most relevant articles for your search:LSE:0REU